170 related articles for article (PubMed ID: 38036592)
1. Proton pump inhibitors and chronic kidney disease risk: a comparative study with histamine-2 receptor antagonists.
Kweon T; Kim Y; Lee KJ; Seo WW; Seo SI; Shin WG; Shin DH
Sci Rep; 2023 Dec; 13(1):21169. PubMed ID: 38036592
[TBL] [Abstract][Full Text] [Related]
2. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.
Lazarus B; Chen Y; Wilson FP; Sang Y; Chang AR; Coresh J; Grams ME
JAMA Intern Med; 2016 Feb; 176(2):238-46. PubMed ID: 26752337
[TBL] [Abstract][Full Text] [Related]
3. Histamine-2 Receptor Antagonists and Proton Pump Inhibitors Are Associated With Reduced Risk of SARS-CoV-2 Infection Without Comorbidities Including Diabetes, Hypertension, and Dyslipidemia: A Propensity Score-Matched Nationwide Cohort Study.
Kim B; Jung JH; Han K; Kang S; Lee E; Chung H; Kim SG; Cho SJ
J Korean Med Sci; 2023 Apr; 38(13):e99. PubMed ID: 37012686
[TBL] [Abstract][Full Text] [Related]
4. Non-indicated initiation of proton pump inhibitor and risk of adverse outcomes in patients with underlying chronic kidney disease: a nationwide, retrospective, cohort study.
Kim SG; Cho JM; Han K; Joo KW; Lee S; Kim Y; Cho S; Huh H; Kim M; Kang E; Kim DK; Park S
BMJ Open; 2024 Jan; 14(1):e078032. PubMed ID: 38286693
[TBL] [Abstract][Full Text] [Related]
5. Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD.
Xie Y; Bowe B; Li T; Xian H; Balasubramanian S; Al-Aly Z
J Am Soc Nephrol; 2016 Oct; 27(10):3153-3163. PubMed ID: 27080976
[TBL] [Abstract][Full Text] [Related]
6. Associations of Proton-Pump Inhibitors and H2 Receptor Antagonists with Chronic Kidney Disease: A Meta-Analysis.
Wijarnpreecha K; Thongprayoon C; Chesdachai S; Panjawatanana P; Ungprasert P; Cheungpasitporn W
Dig Dis Sci; 2017 Oct; 62(10):2821-2827. PubMed ID: 28836158
[TBL] [Abstract][Full Text] [Related]
7. Use of Proton Pump Inhibitors vs Histamine 2 Receptor Antagonists for the Risk of Gastric Cancer: Population-Based Cohort Study.
Shin GY; Park JM; Hong J; Cho YK; Yim HW; Choi MG
Am J Gastroenterol; 2021 Jun; 116(6):1211-1219. PubMed ID: 34074826
[TBL] [Abstract][Full Text] [Related]
8. Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study.
Hart E; Dunn TE; Feuerstein S; Jacobs DM
Pharmacotherapy; 2019 Apr; 39(4):443-453. PubMed ID: 30779194
[TBL] [Abstract][Full Text] [Related]
9. Proton-pump inhibitor vs. H2-receptor blocker use and overall risk of CKD progression.
Cholin L; Ashour T; Mehdi A; Taliercio JJ; Daou R; Arrigain S; Schold JD; Thomas G; Nally J; Nakhoul NL; Nakhoul GN
BMC Nephrol; 2021 Jul; 22(1):264. PubMed ID: 34266395
[TBL] [Abstract][Full Text] [Related]
10. Comparative risk of incidence and clinical outcomes of COVID-19 among proton pump inhibitor and histamine-2 receptor antagonist short-term users: a nationwide retrospective cohort study.
Park J; You SC; Cho J; Park CH; Shin WG; Park RW; In Seo S
BMC Pharmacol Toxicol; 2022 Jan; 23(1):9. PubMed ID: 35039078
[TBL] [Abstract][Full Text] [Related]
11. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury.
Xie Y; Bowe B; Li T; Xian H; Yan Y; Al-Aly Z
Kidney Int; 2017 Jun; 91(6):1482-1494. PubMed ID: 28237709
[TBL] [Abstract][Full Text] [Related]
12. Maintenance Proton Pump Inhibitor Use Associated with Increased All-Cause and Cause-Specific Mortality in Sweden.
Ngwenya S; Simin J; Brusselaers N
Dig Dis Sci; 2023 Jun; 68(6):2252-2263. PubMed ID: 36629968
[TBL] [Abstract][Full Text] [Related]
13. The combined use of anti-peptic agents is associated with an increased risk of osteoporotic fracture: a nationwide case-control study.
Oh DJ; Nam JH; Lee HS; Moon YR; Lim YJ
Korean J Intern Med; 2024 Mar; 39(2):228-237. PubMed ID: 38321358
[TBL] [Abstract][Full Text] [Related]
14. Fracture risk of young adults receiving proton-pump inhibitors and H2-receptor antagonists.
Fedida B; Schermann H; Ankory R; Rotman D; Shichman I; Yoffe V; Shlaifer A; Luger E
Int J Clin Pract; 2019 May; 73(5):e13339. PubMed ID: 30829427
[TBL] [Abstract][Full Text] [Related]
15. Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma.
Van De Sijpe G; Beuselinck B; Van Nieuwenhuyse T; Poncelet R; Bechter O; Albersen M; Roussel E; Baldewijns M; Tack J; Spriet I
Eur J Clin Pharmacol; 2020 Sep; 76(9):1273-1280. PubMed ID: 32474662
[TBL] [Abstract][Full Text] [Related]
16. The use of anti-ulcer agents and the risk of chronic kidney disease: a meta-analysis.
Sun J; Sun H; Cui M; Sun Z; Li W; Wei J; Zhou S
Int Urol Nephrol; 2018 Oct; 50(10):1835-1843. PubMed ID: 29948864
[TBL] [Abstract][Full Text] [Related]
17. Beyond uncertainty: Negative findings for the association between the use of proton pump inhibitors and risk of dementia.
Park SK; Nam JH; Lee H; Chung H; Lee EK; Shin JY
J Gastroenterol Hepatol; 2019 Dec; 34(12):2135-2143. PubMed ID: 31145825
[TBL] [Abstract][Full Text] [Related]
18. Long-term continuous use of proton-pump inhibitors is associated with renal function decline in patients without acute kidney injury.
Hatakeyama Y; Horino T; Matsumoto T; Terada Y; Okuhara Y
Clin Exp Nephrol; 2021 Oct; 25(10):1087-1092. PubMed ID: 34089392
[TBL] [Abstract][Full Text] [Related]
19. Renal Transplant Acute Rejection with Lower Mycophenolate Mofetil Dosing and Proton Pump Inhibitors or Histamine-2 Receptor Antagonists.
Patel KS; Stephany BR; Barnes JF; Bauer SR; Spinner ML
Pharmacotherapy; 2017 Dec; 37(12):1507-1515. PubMed ID: 28976570
[TBL] [Abstract][Full Text] [Related]
20. Proton Pump Inhibitor Use, H
Paik JM; Rosen HN; Gordon CM; Curhan GC
Calcif Tissue Int; 2018 Oct; 103(4):380-387. PubMed ID: 29754277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
